Report : Middle East and Africa Point-of-Care Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product & Services (Assays and Kits, Instruments, and Services and Software), Technology (PCR, Isothermal Nucleic Acid Amplification Technology (INAAT), and Other Technologies), Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and Other Applications), End User (Hospitals and Clinics, Diagnostic Laboratories, Research and Academic Institutes, and Others)
Assays and Kits Segment has the Largest Share of Product & Services in the Middle East & Africa Point-of-Care Molecular Diagnostics Market during 2021–2028
According to our latest study on “Middle East & Africa Point-of-Care Molecular Diagnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product & Services, Technology, Application, and End User,” the market is projected to reach US$ 212.9 million by 2028 from US$ 94.0 million in 2021; it is expected to grow at a CAGR of 12.4% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising incidences of infectious diseases and growing demand for specific viral detection methods that consume less time for timely infection control. However, pricing pressures owing to reimbursement cuts is likely to hamper market growth.
South Africa has reported the highest COVID-19 cases in the Middle East and Africa, followed by Saudi Arabia and the UAE, among others. The Saudi government policies have been favoring the proliferation of domestic pharmaceutical manufacturers; the government has lifted import duties on raw materials and intermediate products and made financing easy by supporting interest-free funding. Similarly, the continuously increasing incidence of COVID-19 is creating a huge demand for kits and reagent used in its diagnosis. In April 2020, BGI Group, a Chinese genomics company, and Group-42, a UAE technology company, unveiled a new massive-throughput laboratory in the UAE to support testing and diagnosis of the novel coronavirus. According to the BGI Group, the lab will use RT-PCR diagnostic kits that have been approved by medical regulatory authorities in China, Europe, the US, and Japan. As point-of-care molecular diagnostics kits are majorly used in the detection of SARS-CoV-2, the pandemic is fueling the market growth.
Based on product & services, the Middle East & Africa Point-of-Care Molecular Diagnostics market is bifurcated into assays and kits, instruments, and services and software. In 2020, the assays and kits segment are estimated to account for the largest market share in the Middle East & Africa point-of-care molecular diagnostics market. POC molecular diagnostic assays and kits are specially designed for point of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts. POC molecular diagnostics assays and kits enable the early diagnosis of infectious diseases, cancer, and women’s health and sexual health conditions among others.
bioMérieux SA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Enzo Biochem, Inc., Abbott, Meridian BioScience, Inc., Biocartis, Quidel Corporation, and Bio-Rad Laboratories, Inc. are among the leading companies in the Middle East & Africa Point-of-Care Molecular Diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for Point-of-Care Molecular Diagnostics market is segmented into product & services, technology, application, and end user. Based on product & services, the Middle East & Africa Point-of-Care Molecular Diagnostics market is segmented into assays and kits, instruments, and services and software. Based on technology, the Point-of-Care Molecular Diagnostics market is segmented into PCR, isothermal nucleic acid amplification technology (INAAT), and other technologies. Based on application, the Point-of-Care Molecular Diagnostics market is segmented into infectious diseases, oncology, hematology, prenatal testing, endocrinology, and other applications. Based on end user, the Point-of-Care Molecular Diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, research and academic institutes, and others. Geographically, the Point-of-Care Molecular Diagnostics market is segmented into Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa).
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org